Latest on Ultrasound Renal Denervation
Published: 22 June 2022
-
Views:
7871
-
Likes:
7
-
Views:
7871
-
Likes:
7
-
Up Next -
21m 53sPart 2 | Session 3 How to build uRDN centre / therapy pathway: Prof Roland Schmieder
-
19m 35s -
11m 41sPart 3 | Session 2 "Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen -
28m 37sPart 3 | Session 3 "How to build Interventional HTN Therapy/Practice": Joachim Weil
-
5m 12sPart 4 | Session 1 RADIANCE II Pivotal Trial -
1h 20s
-
5m 10s -
4m 44s -
16m 20sPart 5 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane -
5m 47sPart 5 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial
-
1h 4m 58sPart 7 | Session 1 ACC 2022 Symposium -
59m 32sPart 7 | Session 2 TCT 2021 Symposium
-
4m 2sPart 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
-
9m 18sPart 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu
-
15m 10sPart 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner
-
18m 36sPart 1 | Session 4 RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Felix Mahfoud
-
10m 14sPart 1 | Session 5 Panel Discussion: All Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
-
15m 15sPart 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp Andrew SP Sharp
Overview
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.
The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
What you will learn:
- How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
- The clinical evidence supporting uRDN and its implications for the field of hypertension
- The process for building a uRDN centre and therapy network
This page is designed for:
- Interventional cardiologists
- General cardiologists
- Hypertension specialists
- Nephrologists
- Interventional radiologists
More from this programme
Part 1
The Science of uRDN
Part 2
The Evidence for uRDN
Part 3
From Proof to Practice – Treating Hypertension With uRDN
Part 4
RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension
Part 5
Results From the Latest Clinical Trials
Part 6
Patient Perspective & Provider Referral Development
Part 7
Discussion With Experts
| 2 sessions | |
| ACC 2022 Symposium | Watch now |
| TCT 2021 Symposium | Watch now |
Faculty Biographies
Felix Mahfoud
Professor of Cardiology and Chairman of the Department of Cardiology
Prof Felix Mahfoud is a Professor of Cardiology at the University of Basel and the Chairman of the Department of Cardiology at University Hospital Basel, Switzerland. He also holds a position as Visiting Professor at Harvard-MIT, Biomedical Engineering in Boston, MA.
Prof Mahfoud is board-certified in internal medicine, cardiology, intensive care medicine, emergency medicine and hypertension. He is Deputy Editor of the European Journal of Heart Failure and is a Councillor on the Board of the European Society of Cardiology (ESC) for 2024-2026. Additionally, he chairs both the ESC Communication Committee and the Scientific Documents Committee of the EAPCI for the 2024-2026 term.
He has published more than 500 publications in peer-reviewed journals and contributed as a wiring committee member to the 2019 ESC Guidelines for the…